CoChat

Effects of canagliflozin on serum potassium in the CANagliflozin cardioVascular Assessment Study (CANVAS) Program

Open access
Weir, Matthew R, Slee, April, Sun, Tao, Balis, Dainius, Oh, Richard, de Zeeuw, Dick, Perkovic, Vlado · 2021 · Clinical Kidney Journal

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Abstract

Background: The sodium-glucose cotransporter 2 inhibitor canagliflozin has been shown to reduce the risk of cardiovascular and renal events in patients with Type 2 diabetes mellitus and high risk. Pooled analyses of data from early studies and interim data from the CANagliflozin cardioVascular Assessment Study (CANVAS) suggested that canagliflozin might lead to increases in serum potassium, particularly the 300 mg dose in patients with renal impairment, which is important because high serum potassium is associated with increased cardiovascular and renal risk. We examined the effect of canagliflozin on serum potassium levels and hyperkalemia rates in the completed CANVAS Program. Methods: The CANVAS Program (n = 10,142) was comprised of two comparable double-blind, randomized, placebo-controlled trials (CANVAS and CANVAS-Renal). Participants received canagliflozin 100 or 300 mg or placebo. Serum potassium measurements were performed in a central laboratory0 and assessed at ∼6-month intervals. Results: In the CANVAS Program, mean potassium levels were generally consistent with canagliflozin and placebo, overall and by baseline estimated glomerular filtration rate (eGFR; ≥60, 45 to<60 and <45 mL/min/1.73 m2). The risk of increased or decreased potassium was similar with canagliflozin and placebo overall and by baseline eGFR (all P-heterogeneity ≥0.56) or use of renin–angiotensin–aldosterone system inhibitors (all P-heterogeneity ≥0.71); levels did not appear different by canagliflozin dose. Hyperkalemia {hazard ratio (HR) [95% confidence interval (CI)] 1.60 (0.92–2.81)} and serious hyperkalemia [HR (95% CI) 0.75 (0.27–2.11)] adverse events were not different across groups. Conclusions: In the CANVAS Program, there were no meaningful effects of canagliflozin on serum potassium in the overall population or key subgroups. Hyperkalemia adverse events were uncommon and occurred at comparable rates with canagliflozin and placebo.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/ckj/sfaa133

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Figures

FIGURE 1: Mean serum potassium in the CANVAS Program (A) overall, and by baseline eGFR (B) ≥60 mL/min/1.73 m2, (C) 45 to <60 mL/min/1.73 m2 and (D) <45 mL/min/1.73 m2. SE, standard error.
FIGURE 1: Mean serum potassium in the CANVAS Program (A) overall, and by baseline eGFR (B) ≥60 mL/min/1.73 m2, (C) 45 to <60 mL/min/1.73 m2 and (D) <45 mL/min/1.73 m2. SE, standard error.CC BY-NC · PubMed Central
FIGURE 2: Participants with serum potassium values outside of specified ranges in the CANVAS Program overall and by baseline eGFR (intent-to-treat analysis, n = 10 140). LLN, lower limit of normal.
FIGURE 2: Participants with serum potassium values outside of specified ranges in the CANVAS Program overall and by baseline eGFR (intent-to-treat analysis, n = 10 140). LLN, lower limit of normal.CC BY-NC · PubMed Central
FIGURE 3: Participants with baseline RAAS inhibitor use with serum potassium values outside of predefined limit of change criteria in the CANVAS Program overall and by baseline eGFR (n = 8114 randomized participants with baseline RAAS inhibitor use and baseline serum potassium measurements). LLN, lower limit of normal.
FIGURE 3: Participants with baseline RAAS inhibitor use with serum potassium values outside of predefined limit of change criteria in the CANVAS Program overall and by baseline eGFR (n = 8114 randomized participants with baseline RAAS inhibitor use and baseline serum potassium measurements). LLN, lower limit of normal.CC BY-NC · PubMed Central
FIGURE 4: Participants with serum potassium values outside of predefined limit of change criteria by canagliflozin dose in the CANVAS study (n = 4328 randomized participants with baseline serum potassium measurements in the CANVAS study). LLN, lower limit of normal.
FIGURE 4: Participants with serum potassium values outside of predefined limit of change criteria by canagliflozin dose in the CANVAS study (n = 4328 randomized participants with baseline serum potassium measurements in the CANVAS study). LLN, lower limit of normal.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 29 references

Cited by

See all 31

Metadata

Authors
Weir, M. R., Slee, A., Sun, T., Balis, D., Oh, R., de Zeeuw, D., & Perkovic, V.
Affiliations
  • University of Maryland, Baltimore (US)
  • Axio Research, Seattle, WA, USA
  • Janssen Research & Development (United States) (US)
  • Department of Clinical Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
  • Royal North Shore Hospital (AU)
Corresponding author
Weir, Matthew R
Venue
Clinical Kidney Journal
Published
2020-09-02
Volume
14
Issue
5
Pages
1396-1402
ISSN
  • 2048-8505 (ISSN-L)
  • 2048-8513
OpenAlex
W3082878703
Cited by
31
References
29
Citations by year
2026: 3 · 2025: 5 · 2024: 2 · 2023: 9 · 2022: 6 · 2021: 6
FWCI
3.96
Type
journal article
Language
en
Open access
Locations
  • Clinical Kidney Journal (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, cc-by-nc)
Funders
Janssen Research & Development, LLC
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Nephrology › Potassium and Related Disorders
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
Keywords
canagliflozin, serum potassium, hyperkalemia, SGLT2 inhibitors, type 2 diabetes, renal dysfunction, EGFR, renin-angiotensin-aldosterone system inhibitors, CANVAS Program, adverse events

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of canagliflozin on serum potassium in the CANagliflozin cardioVascular Assessment Study (CANVAS) Program. https://app.cochat.ai/papers/10.1093/ckj/sfaa133
The paper
Weir, M. R., Slee, A., Sun, T., Balis, D., Oh, R., de Zeeuw, D., & Perkovic, V. (2021). Effects of canagliflozin on serum potassium in the CANagliflozin cardioVascular Assessment Study (CANVAS) Program. Clinical Kidney Journal. https://doi.org/10.1093/ckj/sfaa133

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.